A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries

Table 2 Epidemiological input data: complications and chronic sequelae ¹

	Argentina			Brazil			Chile			Colombia			Mexico			Peru
	Myringot.	Hearing seq	Neurol seq	Myringot.	Hearing seq	Neurol seq	Myringot.	Hearing seq	Neurol seq	Myringot.	Hearing seq	Neurol seq	Myringot.	Hearing seq	Neurol seq	Myringot.	Hearing seq	Neurol seq
All-cause AOM
0-1 years	0.02%	10.0%	-	0.05%	10%	-	0.03%	10%	-	0.07%	10%	-	0.02%	12.50%	-	0.01%	13.50%	-
2-4 years	0.02%	4.00%	-	0.02%	4%	-	0.03%	4.50%	-	0.07%	7.50%	-	0.05%	7.50%	-	0.04%	6.24%	-
5-9 years	0.01%	2.00%	-	0.01%	1%	-	0.02%	2.50%	-	0.01%	2%	-	0.03%	3%	-	0.01%	1.50%	-
Pneumococcal meningitis
0-1 years	-	5.88%	17.63%	-	10%	40%	-	25%	25%	-	56.30%	18.80%	-	12%	28%	-	6%	24%
2-4 years	-	2.34%	14.53%	-	10%	40%	-	11.10%	20.10%	-	25.50%	23.25%	-	4.25%	17%	-	4.30%	23.25%
5-10 years	-	0.70%	9.30%	-	10%	36%	-	5%	15%	-	58.20%	15.28%	-	1.90%	10.60%	-	0.50%	9.50%

ISSN: 1478-7547